| First Author | Hatanaka F | Year | 2024 |
| Journal | Nat Commun | Volume | 15 |
| Issue | 1 | Pages | 6191 |
| PubMed ID | 39048567 | Mgi Jnum | J:355054 |
| Mgi Id | MGI:7706934 | Doi | 10.1038/s41467-024-50095-5 |
| Citation | Hatanaka F, et al. (2024) Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing. Nat Commun 15(1):6191 |
| abstractText | Defect in the SMN1 gene causes spinal muscular atrophy (SMA), which shows loss of motor neurons, muscle weakness and atrophy. While current treatment strategies, including small molecules or viral vectors, have shown promise in improving motor function and survival, achieving a definitive and long-term correction of SMA's endogenous mutations and phenotypes remains highly challenging. We have previously developed a CRISPR-Cas9 based homology-independent targeted integration (HITI) strategy, enabling unidirectional DNA knock-in in both dividing and non-dividing cells in vivo. In this study, we demonstrated its utility by correcting an SMA mutation in mice. When combined with Smn1 cDNA supplementation, it exhibited long-term therapeutic benefits in SMA mice. Our observations may provide new avenues for the long-term and efficient treatment of inherited diseases. |
